Tavapadon
Tavapadon is a novel, selective dopamine D1/D5 receptor partial agonist that is currently under investigation for the treatment of Parkinson's disease. It is being developed by Cerevel Therapeutics, a biopharmaceutical company focused on developing innovative treatments for nervous system disorders.
Mechanism of Action[edit | edit source]
Tavapadon works by selectively targeting and activating the D1/D5 dopamine receptors, which are a subtype of dopamine receptors. Dopamine is a neurotransmitter that plays a crucial role in the regulation of movement, mood, and cognition. In Parkinson's disease, the loss of dopamine-producing neurons leads to a decrease in dopamine levels, resulting in motor symptoms such as tremors, rigidity, and bradykinesia. By activating the D1/D5 receptors, tavapadon is believed to enhance dopamine signaling and thereby improve these motor symptoms.
Clinical Trials[edit | edit source]
Several clinical trials have been conducted to evaluate the safety and efficacy of tavapadon in patients with Parkinson's disease. In a Phase 2 trial, tavapadon demonstrated a significant improvement in motor function and was generally well-tolerated. The most common side effects were nausea, dizziness, and headache. A Phase 3 trial is currently underway to further evaluate the long-term safety and efficacy of tavapadon.
Potential Benefits[edit | edit source]
If approved, tavapadon could offer several potential benefits over existing treatments for Parkinson's disease. It has a novel mechanism of action that directly targets the underlying cause of the motor symptoms. Additionally, as a selective D1/D5 receptor agonist, it may have a better side effect profile compared to non-selective dopamine agonists.
Future Directions[edit | edit source]
The ongoing clinical trials will provide more information about the safety and efficacy of tavapadon in patients with Parkinson's disease. If the results are positive, tavapadon could potentially become a new treatment option for this debilitating disease.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
